Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 0.25 ABIM MOC points
Nurses - 0.25 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)
Pharmacists - 0.25 Knowledge-based ACPE (0.025 CEUs)
Physician Assistant - 0.25 AAPA hour(s) of Category I credit
IPCE - 0.25 Interprofessional Continuing Education (IPCE) credit
This activity is intended for cardiologists, neurologists, critical care clinicians, internists, nurses, pharmacists, physician assistants, and other members of the healthcare team for patients with stroke caused by intracerebral hemorrhage.
The goal of this activity is for members of the healthcare team to be better able to describe the effect of implementing a goal-directed care bundle incorporating hospital protocols for early intensive blood pressure lowering and management algorithms for hyperglycemia, pyrexia, and abnormal anticoagulation on outcomes for patients with acute spontaneous intracerebral hemorrhage, based on the INTERACT3, an international, stepped wedge cluster randomized controlled trial.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.00 contact hours are in the area of pharmacology.
Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number: JA0007105-0000-23-253-H01-P).
Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 06/30/2024. PAs should only claim credit commensurate with the extent of their participation.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive
AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 6/30/2023
Valid for credit through: 6/30/2024, 11:59 PM EST
processing....
Intracerebral hemorrhage (ICH), the most serious and least treatable form of stroke, accounts for approximately 20% of nearly 20 million new strokes occurring globally each year, mostly in low- and middle-income countries with high prevalence of hypertension, high salt intake, and other risk factors.
Combinations of interventions may be more effective in ICH than blood pressure lowering alone. INTERACT2 showed that higher scores for any elevation in systolic blood pressure, glucose, temperature, and previous anticoagulant use independently predicted poor functional outcome after ICH.
A combination of simple interventions for acute patients with stroke attributable to ICH has been shown to significantly improve the chances of survival without major disability.
The INTERACT3 study showed that timely administration of a care bundle that included early intensive lowering of systolic blood pressure, strict glucose control, treatment of fever, and rapid reversal of abnormal anticoagulation led to less disability, lower rates of death, and better overall quality of life.
“This is a groundbreaking result. It is the first ever published trial in ICH patients to show a clear benefit on functional outcomes and on mortality,” lead investigator Craig Anderson, MD, director of global brain health at the George Institute, Sydney, Australia, told theheart.org | Medscape Cardiology.
“These results show that if we can organize care and focus on optimal management of these 4 aspects of the health of the patient, they do better,” Dr Anderson said.
“Game Changer”
“This is a game changer because now we have level A evidence showing something is definitely beneficial for these patients.” Dr Anderson added. “That means hospitals have the imperative to organize their systems to do these things and maximize care. We have never had that before.”
Dr Anderson noted that although some previous studies have suggested benefit from various interventions, such as early lowering of blood pressure, the results have not been conclusive.
“This means the intervention has not always been implemented, leading to large variations in clinical practice. But now we have a package that is proven to work, this should become a guideline-recommended practice,” he commented.
The INTERACT-3 results were presented on May 25 at the European Stroke Organisation Conference in Munich, Germany. They were also simultaneously published online in the Lancet.[1]
Dr Anderson explained that until now, there have not been any proven treatments for ICH. “There has been a lot of energy and research put into the field, but this has resulted in several interventions that are ‘probably useful’ or which have a level B recommendation,” he said. “No therapy has been shown to be beneficial in a totally conclusive way, so we are still not entirely sure exactly whether the treatments we use actually make a difference.”
The INTERACT3 researchers therefore decided to evaluate a care package consisting of a bundle of several treatments in the hope that they may have additive or synergistic effects.
The study involved 7036 patients with imaging-confirmed spontaneous ICH who presented within 6 hours of symptom onset to 1 of 121 hospitals in 10 mainly low- and middle-income countries: Brazil, China, India, Mexico, Nigeria, Pakistan, Peru, Sri Lanka, Vietnam, and Chile.
Using a cluster design, all hospitals started with usual care as a control, and then at some point during the study started using the care bundle intervention.
The care bundle protocol included the early intensive lowering of systolic blood pressure (target, <140 mm Hg), strict glucose control (target, 6.1-7.8 mmol/L in those without diabetes and 7.8-10.0 mmol/L in those with diabetes), antipyrexia treatment (target body temperature, ≤37.5° C), and rapid reversal of warfarin-related anticoagulation (target international normalized ratio, <1.5) in patients for whom these variables were abnormal.
Overall, the modified intention-to-treat population included 3221 patients who were assigned to the care bundle group and 3815 who were assigned to the usual care group. Primary outcome data were available for 2892 patients in the care bundle group and 3363 patients in the usual care group.
The primary outcome was functional recovery, measured with the modified Rankin scale at 6 months. Results show that the likelihood of a poor functional outcome was lower in the care bundle group (common odds ratio, 0.86; P=.015).
Patients who received the interventional care bundle also had a significantly lower rate of serious adverse events (16.0% vs 20.1%) and mortality (14.1% vs 17.0%).
Number Needed to Treat of 35 to Save One Life Free of Disability
“The number needed to treat is just 35 to save a life free of disability,” Dr Anderson commented. “That’s pretty good. We estimate that this care bundle would save tens of thousands of lives a year if universally adopted.”
The intervention group also spent less time in hospital and had improved health-related quality of life.
Dr Anderson pointed out that the interventions included in the care bundle were all relatively easy to perform: “They just require a bit more nursing time and the use of a few inexpensive medicines and maybe infusion pumps, but we’re not talking about the need for skilled surgery or a new therapy costing hundreds of thousands of dollars, so this care bundle should be very straightforward to implement. While we haven’t done a formal cost-effectiveness analysis, I would say it will definitely be good value for money.”
Dr Anderson believes that the rapid lowering of blood pressure is a very important part of the care bundle. He noted that target levels were achieved, on average, in 2.3 hours compared with 4.0 hours in the control group. But he stressed that this was not just a trial of blood pressure reduction, and that the whole package is important.
He gave a couple of possible reasons why this trial was successful, whereas previous trials did not show a clear benefit of blood pressure lowering in ICH.
“Firstly, it was a very large trial with more than 7000 patients; that is more than 3 times larger than any other trial in ICH. And secondly, the package of care means there are several different interventions that together show a real benefit,” he said. “It’s like the polypill, or a rehabilitation program: If you put several different things together, the whole package can show really positive results.”
Dr Anderson also pointed out that the study included a wide spectrum of patients with ICH, and the benefit of the care bundle was seen across all groups and all stroke severities.
“There were a lot of patients with a large ICH, and if anything, they showed an even larger benefit with the bundle of care,” he said.
The researchers note that the burden of ICH is greatest in low- and middle-income countries. This is in part attributable to high rates of hypertension and limited resources for primary prevention, including identification and management of stroke risk factors by healthcare services.
“Outstanding Example” of Less Therapeutic Negativity
Lili Song, MD, PhD, joint lead author and head of the Stroke Program at the George Institute China, said, “A lack of proven treatments for ICH has led to a pessimistic view that not much can be done for these patients.
“However, with INTERACT3, we demonstrate on a large scale how readily available treatments can be used to improve outcomes in resource-limited settings,” she noted. “We hope this evidence will inform clinical practice guidelines across the globe and help save many lives.”
The INTERACT3 study was funded by the Department of Health and Social Care; the Foreign, Commonwealth and Development Office; the Medical Research Council; and the Wellcome Trust in the United Kingdom, as well as the West China Hospital Outstanding Discipline Development 1-3-5 Programme, the National Health and Medical Research Council of Australia, Sichuan Credit Pharmaceutical, and Takeda in China.
European Stroke Organisation Conference (ESOC) 2023: Presented May 25, 2023.
Lancet. Published online May 25, 2023.